In OS, specifically, INF-α inhibits cancer clones in vitro and enhances OS sensitivity to chemotherapeutic drugs as doxorubicin, despite showing conflicting evidence regarding survival improvement and tumor regression (in patients with metastatic OS) in clinical trials [92]. The gene discussed is IFNA17; the disease is cancer.